LBA61A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer

ConclusionsCompared to physician ’s choice SOC, TRAM was associated with significantly improved PFS and ORR in women with recurrent LGSOC.Clinical trial identificationNCT02101788.Legal entity responsible for the studyNational Cancer Institute (NRG Oncology).FundingNational Cancer Institute (US) and Novartis.DisclosureW. Brady: Full / Part-time employment: Sarah Cannon Development Innovations. R.L. Coleman: Advisory / Consultancy, Leadership role, Research grant / Funding (self), Non-remunerated activity/ies: AbbVie; Honoraria (self), Advisory / Consultancy: aravive; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Non-remunerated activity/ies: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: clovis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Roche Genentech; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Novartisjavascript:%20create_table_line( ’1’,%20new%20Array(’ent’,%20’des’,%20’tor’));; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Janssen; Honoraria (self), Research grant / Funding (self), Re...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research